Нутрацеутици хмеља у сусрет терапији метастатског меланома
Nutraceuticals from hops in the treatment of metastatic melanoma
2023
Download 🢃
Authors:
Krajnović, TamaraMaksimović-Ivanić, Danijela
Mijatović, Sanja
Contributors
Arsenijević, NebojšaDocument Type:
Conference object (Published version)
,
© 2023 by the Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine, Kragujevac, Serbia
Metadata
Show full item recordAbstract:
Melanoma is considered the most aggressive type of skin cancer. Due to initial or
acquired resistance and numerous side effects, existing therapeutic regimens for metastatic
melanoma are not sufficiently effective. Therefore, melanoma remains associated with a
high mortality rate. Despite extensive therapeutic protocols, the curation rate for invasive
forms of tumors is quite low, and the question arises as to what is wrong with the current
approach in oncotherapy. The main criterion for the selection of new antitumor drugs is
primarily based on their ability to induce apoptosis. However, numerous literature data
link aggressive therapeutic approaches based on the induction of apoptosis in high grade
tumors, which are characterized by the presence of cells with a low-differentiated
phenotype, with tumor progression that occurs due to compensatory proliferation. The
solution to the problem lies in increasing the level of tumor differentiation, which will
decrease proliferation induced by apoptosis. Differentiation therapy represents a new
concept in the therapy of aggressive malignancies. Many differentiation agents are of
natural origin. In order to increase the efficacy and reduce the toxicity of conventional
therapies, standard therapeutic protocols are often combined with complementary
medicine, where the leading position is occupied by natural products isolated from
plants. Flavonoids are one of the largest and most diverse classes of secondary plant
metabolites, well-known for their pronounced anticancer potential. Prenylflavonoids
from the hop plant have a great potential to trigger a change of the malignant phenotype
into a quiescent, more functionally defined form, closer to the healthy counterpart of the
same or different tissue. This approach has mainly been unexplored, opening up many
possibilities in both scientific and commercial terms. The focus of this lecture will be
on prenylflavonoid - isoxanthohumol in the context of possible melanoma therapy and
the creation of protocols that would increase the effectiveness of existing conventional
chemotherapy.
Keywords:
melanoma; prenylflavonids; chemotherapy; differentiationFunding / projects:
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200007 (University of Belgrade, Institute for Biological Research 'Siniša Stanković') (RS-MESTD-inst-2020-200007)
In:
- Arsenijević N, editor. Abstract Book: The second Serbian Molecular Medicine Congress; 2023 Oct 6-8; Foča, Bosnia and Herzegovina. Kragujevac: Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine; 2023. p. 81-4.